Not for release to U.S. wire services or distribution in the United States

Media Release

12 December 2024

Syntara completes strongly supported placement to raise A$15m

- **Syntara receives firm commitments to raise approximately A$15.0 million via two-tranche placement at A$0.06 per share.**
- **The funds raised will fund myelofibrosis (MF) combination clinical trials, iRBD/Parkinson's and scar trials, MDS clinical trials, drug development, employee research costs, general working capital and capital raising costs.**
- **The Placement follows positive interim results from the Company's Phase 2 study of SNT-5505 in MF.**
- **Syntara will have a strong post-deal cash balance of approximately A$21.7 million.**

Clinical stage drug development company Syntara Ltd (ASX: **SNT** or **Company**) is pleased to announce that it has received firm commitments from new and existing institutional and high net worth investors to raise approximately A$15.0m by way of a two-tranche placement comprising:

- The issue of approximately 206 million fully paid ordinary shares at A$0.06 per share, to raise approximately A$12.4 million via a placement within the Company's 15% placement capacity under ASX Listing Rule 7.1 (**Tranche 1**); and
- The issue of approximately 44 million fully paid ordinary shares at A$0.06 per share, to raise another approximately A$2.6 million (**Tranche 2**) (together with Tranche 1, the **Placement**). Tranche 2 requires shareholder approval as it exceeds the Company's 15% placement capacity under ASX Listing Rules 7.1 and includes a A$0.58m investment by KP Rx, a fund managed by a director of the Company. A General Meeting to approve Tranche 2 and the participation by KP Rx is expected to be convened for late January / early February 2025.

The funds raised from the Placement will provide funding for the Company's MF combination clinical trials, iRBD/Parkinson's and scar trials, MDS clinical trial, drug

development and employee research costs, in addition to general working capital purposes and capital raising costs.

Gary Phillips, Chief Executive Officer of Syntara, commented: “We’re very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive interim data we announced earlier this week in our SNT-5505 MF program. With this injection of capital Syntara is now very well positioned to take this program toward a pivotal Phase 2c/3 study.”

Canaccord Genuity and Euroz Hartleys have been appointed as Joint Lead Managers to the Placement.

Placement Details

The shares to be issued under the Placement will be issued at a price of A$0.06 per share, a discount of approximately 10.4% to the last traded price on 9 December 2024 (A$0.067), a premium of approximately 10.4% to the 30-day VWAP (A$0.054) up to and including 9 December 2024 and 114.3% higher than the placement announced in July 2024 (at A$0.028).

Quotation and trading of the new shares issued under Tranche 1 are expected to take place on Thursday 19 December 2024.

Quotation and trading of new shares issued under Tranche 2 are expected to take place following a General Meeting to be held in late January or early February 2025.

#ENDS#

SOURCE:
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Board.

Contact: David McGarvey, Company Secretary:

+61 2 8760 1480,
david.mcgarvey@syntaraTX.com.au

CONTACT:

Syntara Investor/media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST HERE

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further three potential phase 1c/2 studies being evaluated for 2025 Lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a further phase 2 myelofibrosis study with interim data by Q4 2024. Protocols for another two phase 1c/2 studies with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome are in development and expected to commence recruitment by Q1 2025.

Syntara is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaratx.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.